Swiss regulator gives green light to first drug to prevent Covid-19
Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis drug approved by the Swiss medical regulator.
This content was published on
2 minutes
Keystone-SDA/jdp
Русский
ru
Швейцарский регулятор одобрил препарат для профилактики Covid-19
This authorisation means that the drug, which is administered as an injection, can now be reimbursed by the federal government or health insurance under certain conditions. Evusheld, which is an antibody combination of Tixagevimab and Cilgavimab, is intended for people 12 years and older who aren’t able to build up sufficient immune defenses against Covid-19 from vaccines.
The federal government has already signed contracts with AstraZeneca’s Swiss subsidiary to procure the Covid-19 drug starting with 5,000 doses, according to Keystone-SDA.
Evusheld is authorised for use for Covid-19 prevention in the United States (emergency use), Japan, the European Union and several other countries.
In the UK, where AstraZeneca has its headquarters, officials recently saidExternal link they will not purchase the drug citing “insufficient data” on the duration of protection it provides against the dominant variant Omicron and its subvariants.
On Friday, the EU extended its recommendation for the drug so that it can also be used as a treatment. Swissmedic is still reviewing Evusheld for use as a treatment. However, Swiss Covid regulations allow for the drug to be used to treat Covid-19 patients under certain conditions as the company’s application is being reviewed.
Other treatments
On Friday, the World Health Organization rescinded recommendations for two Covid-19 antibody therapies, stating that new variants have rendered them obsolete.
The two therapies, sotrovimab and casirivimab-imdevimab, were designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells.
GSK and partner Vir Biotechnology’s sotrovimab was pulled off the US market by the Food and Drug Administration (FDA) in April.
In January, the FDA also revised its stance on Casirivimab-imdevimab, which is sold under the name REGEN-COV. It limited the use of the drug sold by Swiss firm Roche and US firm Regeneron to a smaller group of patients, citing that it is less effective against the Omicron variant.
Macron will attend Swiss summit on Ukraine, says Zelensky
This content was published on
French President Emmanuel Macron will attend the peace conference on Ukraine at the Swiss Bürgenstock resort next month, according to Volodymyr Zelensky.
Top politician tells ‘corrupt’ Eurovision to stay away from Bern
This content was published on
A social media post by the president of Bern’s cantonal government critical of the Eurovision Song Contest has created waves and will be discussed in the cantonal parliament.
Swiss centre records over 200 victims of human trafficking
This content was published on
Last year 317 people took part in a protection programme run by the Specialist Unit for Trafficking in Women and Women’s Migration (FIZ) in German-speaking Switzerland.
This content was published on
The Geneva-based International Committee of the Red Cross (ICRC) and partners are opening a field hospital in southern Gaza on Tuesday.
Lack of smartphone sustainability in Switzerland hits environment
This content was published on
Almost half of all Swiss citizens hang on to their old smartphones, tablets and laptops, according to the Federal Statistical Office.
Police clear out pro-Palestinian students protesting in Geneva
This content was published on
The police intervened early on Tuesday to dislodge pro-Palestinian students who had been occupying the University of Geneva for almost a week.
New gel developed in Zurich renders alcohol harmless
This content was published on
A newly developed gel composed of whey proteins breaks down alcohol in the body and could reduce its harmful and intoxicating effects in humans.
Pro-Palestine protests extend to Basel and Fribourg universities
This content was published on
Demonstrators called for an academic boycott of all Israeli institutions and disassociation with Chaim Weizmann, the first Israeli president.
Explainer: How ready is Switzerland for a new wave of Covid-19?
This content was published on
Covid-19 cases are on the rise again, sparking renewed talk of vaccination and a possible return to social distancing in the autumn.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.